Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
- Author(s)
- Basser, RL; O'Flaherty, E; Green, M; Edmonds, M; Nichol, J; Menchaca, DM; Cohen, B; Begley, CG;
- Details
- Publication Year 2002-04-01,Volume 99,Issue #7,Page 2599-2602
- Journal Title
- BLOOD
- Publication Type
- Journal Article
- Abstract
- Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated with its use. We here report a case of pancytopenia associated with the development of neutralizing antibodies to TPO that occurred in a patient who had undergone multicycle chemotherapy with multiple cycles of subcutaneous administration of pegylated recombinant human megakaryocyte growth and development factor. Samples of the patient's bone marrow showed trilineage hypoplasia with absence of myeloid, erythroid, and megakaryocyte progenitor cells but with elevated endogenous levels of erythropoietin, granulocyte colony-stimulating factor, and stem-cell factor. To our knowledge, this is the first report of an aplastic anemia-like syndrome associated with neutralizing antibodies to TPO. (C) 2002 by The American Society of Hematology.
- Publisher
- AMER SOC HEMATOLOGY
- Keywords
- COLONY-STIMULATING FACTOR; STEM-CELL FACTOR; BLOOD PROGENITOR CELLS; C-MPL; ADVANCED CANCER; POLYETHYLENE-GLYCOL; MICE LACKING; PEG-RHUMGDF; HUMAN SERUM; PHASE-I
- Publisher's Version
- https://doi.org/10.1182/blood.V99.7.2599
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2002-04-01 12:00:00